HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety ...

Advances in precision medicine are reshaping the management of gynecologic cancers, with molecular profiling, biomarker-guided treatment selection, targeted ...

A chemotherapy-free regimen for advanced/recurrent endometrial cancer achieved durable disease control in a substantial ...

Investigators sought to determine whether abemaciclib plus letrozole showed clinically meaningful activity in patients with advanced or recurrent endometrioid endometrial cancer.

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

Data from the SISTER study show that 1:1 peer support significantly increases the odds that Black women with endometrial cancer will complete treatment, according to research pres ...

O'Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center discussed the rationale and early progress of a phase 1/2 ...

Background: Survivors of cancer in adolescence and young adulthood are at increased risk for subsequent primary neoplasms, but studies using Canadian data are limited. We sought to quantify the risk ...

Current tests for endometrial cancer often rely on procedures like transvaginal ultrasound and tissue biopsy to evaluate the ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades. The most ...

Dr. Lili Yang and Dr. Sanaz Memarzadeh have developed an immunotherapy that has achieved complete tumor elimination in mouse models of endometrial cancer. UCLA researchers have developed a CAR-NKT ...

OMAHA, Neb. (WOWT) - An Omaha woman diagnosed with endometrial cancer days before her 43rd birthday is now partnering with her oncologist to raise awareness about symptoms she says many women are too ...